Goat Anti-COL1A2 Antibody – Cat# MBS670615

Human gastric cancer tissue was stained with Goat Anti-Type I Collagen-BlOT (MBS674546) followed by 5treptavidin-HRP (MBS674979).

Type I Collagen (COL1A2) Antibody – Goat

Name: COL1A2 Antibody; Goat; MyBioSource
Brand: MyBioSource
SKU: MBS670615
Price: 615 USD
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS670615

MBS670615 is an antibody targeting COL1A2. Also known as Goat Anti-Type I Collagen-FITC. Host: Goat. More details

$615 / 0.2 mg +1 FREE 8GB USB

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Type I Collagen (COL1A2), Antibody

Full Product Name

Goat Anti-Type I Collagen-FITC

Product Gene Name

anti-COL1A2 antibody

Isotype

IgG

Host

Goat

Purity/Purification

Affinity chromatography on type I collagen covalently linked to agarose

Specificity

Reacts with conformational determinants on type I collagen
Referenced species reactivities include – Human; Chicken; Hamster; Mouse; Chinchilla; Porcine; Rat; Elephant; Rabbit ; Bovine 6; Feline; Sheep; Canine; Guinea Pig; Tree Shrew.

Preparation and Storage

Store at 2-8 degree C

OMIM

120160

3D Structure

ModBase 3D Structure for P08123

Source

Pooled antisera from goats hyperimmunized with type I collagen

Cross Adsorption

Collagen types II, III, IV, V, and VI

Applications Tested/Suitable for anti-COL1A2 antibody

ELISA (EIA), FLISA

Application Notes for anti-COL1A2 antibody

FLISA:
FITC and AF488 conjugates 1:200-1:400
Other Applications: Since applications vary, you should determine the optimum working dilution for product that is appropriate for your specific need.

Product References and Citations for anti-COL1A2 antibody

1. Rasmussen LM, Hansen PR, Ledet T. Homocysteine and the production of collagens, proliferation and apoptosis in human arterial smooth muscle cells. APMIS. 2004;112:598-604. (ELISA, Human Reactivity)
2. Kottler UB, Jünemann AG, Aigner T, Zenkel M, Rummelt C, Schlötzer-Schrehardt U. Comparative effects of TGF-beta1 and TGF-beta2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenons capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp Eye Res. 2005;80:121-34. (ELISA, Human Reactivity)
3. Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, et al. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology. 2010;49:2024-36. (ELISA, WB, Human Reactivity)
4. Zhang WW, Ma KC, Andersen O, Sourander P, Tollesson PO, Olsson Y. The microvascular changes in cases of hereditary multi-infarct disease of the brain. Acta Neuropathol. 1994;87:317-24. (IHC-PS, Human Reactivity)
5. Van Deijnen JH, Van Suylichem PT, Wolters GH, Van Schilfgaarde R. Distribution of collagens type I, type III and type V in the pancreas of rat, dog, pig and man. Cell Tissue Res. 1994;277:115-21. (IHC-PS, Canine, Human, Porcine, & Rat Reactivity)
6. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA. 1999;96:2645-50. (IHC-PS, Bovine Reactivity)
7. Dorotka R, Bindreiter U, Macfelda K, Windberger U, Nehrer S. Marrow stimulation and chondrocyte transplantation using a collagen matrix for cartilage repair. Osteoarthritis Cartilage. 2005;13:655-64. (IHC-PS, Sheep Reactivity)
8. Weissengruber GE, Egerbacher M, Forstenpointner G. Structure and innervation of the tusk pulp in the African elephant (Loxodonta africana). J Anat. 2005;206:387-93. (IHC-PS, Elephant Reactivity)
9. Walter I, Schönkypl S. Extracellular matrix components and matrix degrading enzymes in the feline placenta during gestation. Placenta. 2006;27:291-306. (IHC-PS, Feline Reactivity)
10. Alcazar O, Cousins SW, Striker GE, Marin-Castano ME. (Pro)renin receptor is expressed in human retinal pigment epithelium and participates in extracellular matrix remodeling. Exp Eye Res. 2009;89:638-47. (IHC-PS, WB, Human Reactivity)
11. Chen W, Yu M, Li Y, Chen W, Xia Y. Beneficial effects of astragalus polysaccharides treatment on cardiac chymase activities and cardiomyopathy in diabetic hamsters. Acta Diabetol. 2010;47 Suppl 1:S35-46. (IHC-PS, Hamster Reactivity)
12. Kyller M, Witter K, Tichy F. Gingival stippling in dogs: clinical and structural characteristics. Res Vet Sci. 2010;88:195-202. (IHC-PS, Canine Reactivity)
13. Zhang Y, Edgley AJ, Cox AJ, Powell AK, Wang B, Kompa AR, et al. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur J Heart Fail. 2012;14:549-62. (IHC-PS, WB, Rat Reactivity)
14. Jiang L, Zhou Y, Xiong M, Fang L, Wen P, Cao H, et al. Sp1 mediates microRNA-29c-regulated type I collagen production in renal tubular epithelial cells. Exp Cell Res. 2013;319:2254-65. (IHC-PS, ICC, WB, Rat Reactivity)
15. Sun S, Zhao T, Zhang H, Huang X, Zhang W, Zhang L, et al. Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. Clin Exp Pharmacol Physiol. 2015;42:662-70. (IHC-PS, WB, Rat Reactivity)
16. Jerdan JA, Michels RG, Glaser BM. Extracellular matrix of newly forming vessels—an immunohistochemical study. Microvasc Res. 1991;42:255-65. (IHC-FS, Guinea Pig & Rabbit Reactivity)
17. Miyaishi O, Sakata K, Matsuyama M, Saga S. Distribution of the collagen binding heat-shock protein in chicken tissues. J Histochem Cytochem. 1992;40:1021-9. (IHC-FS, Chicken Reactivity)
18. Dixon IM, Ju H, Reid NL, Scammell-La Fleur T, Werner JP, Jasmin G. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol. 1997;29:1837-50. (IHC-FS, Hamster Reactivity)
19. Harada T, Juhn SK, Kim Y, Sakakura Y. Immunohistochemical localization of collagen types I, III, and IV, laminin, fibronectin, and keratin in the endolymphatic sac. Ann Otol Rhinol Laryngol. 2000;109:180-6. (IHC-FS, Chinchilla Reactivity)
20. Fraser SA, Crawford A, Frazer A, Dickinson S, Hollander AP, Brook IM, et al. Localization of type VI collagen in tissue-engineered cartilage on polymer scaffolds. Tissue Eng. 2006;12:569-77. (IHC-FS, Bovine & Human Reactivity)
21. Chun SY, Lim GJ, Kwon TG, Kwak EK, Kim BW, Atala A, et al. Identification and characterization of bioactive factors in bladder submucosa matrix. Biomaterials. 2007;28:4251-6. (IHC-FS, Porcine Reactivity)
22. Albon J, Farrant S, Akhtar S, Young R, Boulton ME, Smith G, et al. Connective tissue structure of the tree shrew optic nerve and associated ageing changes. Invest Ophthalmol Vis Sci. 2007;48:2134-44. (IHC-FS, Tree Shrew Reactivity)
23. Behmoaras J, Diaz AG, Venda L, Ko J, Srivastava P, Montoya A, et al. Macrophage epoxygenase determines a profibrotic transcriptome signature. J Immunol. 2015;194:4705-16. (IHC-FS, Rat Reactivity)
24. Kothapalli D, Liu S, Bae YH, Monslow J, Xu T, Hawthrone EA, et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Rep. 2012;2:1259-71. (IHC-FS, ICC, Mouse Reactivity)
25. Lundquist P, Ritchie HH, Moore K, Lundgren T, Linde A. Phosphate and calcium uptake by rat odontoblast-like MRPC-1 cells concomitant with mineralization. J Bone Miner Res. 2002;17:1801-13. (ICC, Rat Reactivity)
26. via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene. 2009;28:1285-97. (ICC, WB, Human Reactivity)?Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-
27. Wang J, Chu ES, Chen H, Man K, Go MY, Huang XR, et al. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget. 2015;6:7325-38. (ICC, WB, Human, Mouse, & Rat Reactivity)
28. Marangoni RG, Korman BD, Wei J, Wood TA, Graham LV, Whitfield ML, et al. Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol. 2015;67:1062-73. (ICC, WB, Mouse Reactivity)
29. Dingemans KP, Teeling P, Lagendikj JH, Becker AE. Extracellular matrix of the human aortic media: an ultrastructural histochemical and immunohistochemical study of the adult aortic media. Anat Rec. 2000;258:1-14. (EM, Human Reactivity)
30. Sharawy M, Ali AM, Choi W. Experimental induction of anterior disk displacement of the rabbit craniomandibular joint: an immuno-electron microscopic study of collagen and proteoglycan occurrence in the condylar cartilage. J Oral Pathol Med. 2003;32:176-84. (EM, Rabbit Reactivity)
31. Rodrigues MT, Lee SJ, Gomes ME, Reis RL, Atala A, Yoo JJ. Amniotic fluid-derived stem cells as a cell source for bone tissue engineering. Tissue Eng Part A. 2012;18:2518-27. (EM, Human Reactivity)
32. Xu S, Vancheeswaran R, Bou-Gharios G, O'Hare MJ, Olsen I, Abraham D, et al. Scleroderma-derived human fibroblasts retain abnormal phenotypic and functional characteristics following retroviral transduction with the SV40 tsT antigen. Exp Cell Res. 1995;220:407-14. (FC, Human Reactivity)
33. Mendoza FA, Piera-Velazquez S, Farber JL, Feghali-Bostwick C, Jiménez SA. Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2016;68:210-7. (WB, Human Reactivity)
34. Sato M, Shegogue D, Hatamochi A, Yamazaki S, Trojanowska M. Lysophosphatidic acid inhibits TGF-beta-mediated stimulation of type I collagen mRNA stability via an ERK-dependent pathway in dermal fibroblasts. Matrix Biol. 2004;23:353-61. (IP, Human Reactivity)
35. Reynaert H, Rombouts K, Jia Y, Urbain D, Chatterjee N, Uyama N, et al. Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells. Br J Pharmacol. 2005;146:77-88. (IP, Rat Reactivity)

Other Notes

Small volumes of anti-COL1A2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for COL1A2. It may not necessarily be applicable to this product.

NCBI GI #

30102

NCBI GeneID

1278

NCBI Accession #

CAA39142.1

UniProt Primary Accession #

P08123

UniProt Secondary Accession #

P02464; Q13897; Q13997; Q13998; Q14038; Q14057; Q15177; Q15947; Q16480; Q16511; Q7Z5S6

UniProt Related Accession #

P08123

NCBI Official Full Name

type I collagen, partial

NCBI Official Synonym Full Names

collagen type I alpha 2

NCBI Official Symbol

COL1A2

NCBI Official Synonym Symbols

OI4

UniProt Protein Name

Collagen alpha-2(I) chain

UniProt Synonym Protein Names

Alpha-2 type I collagen

Protein Family

Collagen

UniProt Gene Name

COL1A2

UniProt Entry Name

CO1A2_HUMAN

NCBI Protein Information

collagen alpha-2(I) chain

NCBI Summary for COL1A2

This gene encodes the pro-alpha2 chain of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIB, recessive Ehlers-Danlos syndrome Classical type, idiopathic osteoporosis, and atypical Marfan syndrome. Symptoms associated with mutations in this gene, however, tend to be less severe than mutations in the gene for the alpha1 chain of type I collagen (COL1A1) reflecting the different role of alpha2 chains in matrix integrity. Three transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008]

UniProt Comments for COL1A2

COL1A2: Type I collagen is a member of group I collagen (fibrillar forming collagen). Defects in COL1A2 are the cause of Ehlers-Danlos syndrome type 7B (EDS7B). EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7B is marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations. Defects in COL1A2 are a cause of osteogenesis imperfecta type 1 (OI1). A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta. Defects in COL1A2 are a cause of osteogenesis imperfecta type 2 (OI2); also known as osteogenesis imperfecta congenita (OIC) or lethal perinatal. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency. Defects in COL1A2 are the cause of Ehlers-Danlos syndrome autosomal recessive cardiac valvular form (EDSCV). A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. In addition to joint laxity, skin hyperextensibility and friability, and abnormal scar formation, patients have mitral valve prolapse and insufficiency, mitral regurgitation, and aortic insufficiency. Defects in COL1A2 are a cause of osteogenesis imperfecta type 3 (OI3). A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta. Defects in COL1A2 are a cause of osteogenesis imperfecta type 4 (OI4); also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta. A chromosomal aberration involving COL1A2 may be a cause of lipoblastomas, which are benign tumors resulting from transformation of adipocytes, usually diagnosed in children. Translocation t(7;8)(p22;q13) with PLAG1. Belongs to the fibrillar collagen family.

Protein type: Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 7q22.1

Cellular Component: collagen type I; endoplasmic reticulum lumen; extracellular matrix; extracellular region; extracellular space

Molecular Function: extracellular matrix structural constituent; identical protein binding; metal ion binding; platelet-derived growth factor binding; protein binding; protein binding, bridging; SMAD binding

Biological Process: blood coagulation; blood vessel development; collagen catabolic process; collagen fibril organization; extracellular matrix organization and biogenesis; leukocyte migration; odontogenesis; platelet activation; regulation of blood pressure; regulation of immune response; Rho protein signal transduction; skeletal development; skin morphogenesis; transforming growth factor beta receptor signaling pathway

Disease: Ehlers-danlos Syndrome, Autosomal Recessive, Cardiac Valvular Form; Ehlers-danlos Syndrome, Type Vii, Autosomal Dominant; Osteogenesis Imperfecta, Type Ii; Osteogenesis Imperfecta, Type Iii; Osteogenesis Imperfecta, Type Iv; Osteoporosis

Research Articles on COL1A2

1. Collagen I mutation analysis(COL1A1 and COL1A2 ) was performed in the family of 97% of known cases, with causative mutations found in 87%. Qualitative mutations caused 32% of Osteogenesis imperfecta type I.

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Products associated with anti-COL1A2 antibody

Reference Product	PubMed Publications
COL1A1 antibody	>408 publications with COL1A2 and COL1A1
JUN antibody	>138 publications with COL1A2 and JUN
SMAD3 antibody	>64 publications with COL1A2 and SMAD3
SP1 antibody	>41 publications with COL1A2 and SP1
LEPRE1 antibody	>24 publications with COL1A2 and LEPRE1
LUM antibody	>7 publications with COL1A2 and LUM
COL5A3 antibody	>1 publications with COL1A2 and COL5A3
ITGA2 antibody	>1 publications with COL1A2 and ITGA2

Pathways associated with anti-COL1A2 antibody

Products by Pathway	Pathway Diagram
AGE-RAGE Signaling Pathway In Diabetic Complications antibodies	AGE-RAGE Signaling Pathway In Diabetic Complications Diagram
AGE-RAGE Signaling Pathway In Diabetic Complications antibodies	AGE-RAGE Signaling Pathway In Diabetic Complications Diagram
Amoebiasis Pathway antibodies	Amoebiasis Pathway Diagram
Amoebiasis Pathway antibodies	Amoebiasis Pathway Diagram
Assembly Of Collagen Fibrils And Other Multimeric Structures Pathway antibodies	Assembly Of Collagen Fibrils And Other Multimeric Structures Pathway Diagram
Binding And Uptake Of Ligands By Scavenger Receptors Pathway antibodies	Binding And Uptake Of Ligands By Scavenger Receptors Pathway Diagram
C-MYB Transcription Factor Network Pathway antibodies	C-MYB Transcription Factor Network Pathway Diagram
Collagen Biosynthesis And Modifying Enzymes Pathway antibodies	Collagen Biosynthesis And Modifying Enzymes Pathway Diagram
Collagen Formation Pathway antibodies	Collagen Formation Pathway Diagram
ECM-receptor Interaction Pathway antibodies	ECM-receptor Interaction Pathway Diagram

Diseases associated with anti-COL1A2 antibody

Disease Name	Pubmed Publications
Fibrosis Antibodies	>214 publications with COL1A2 and Fibrosis
Cardiovascular Diseases Antibodies	>102 publications with COL1A2 and Cardiovascular Diseases
Inflammation Antibodies	>57 publications with COL1A2 and Inflammation
Scleroderma, Systemic Antibodies	>51 publications with COL1A2 and Scleroderma, Systemic
Liver Diseases Antibodies	>48 publications with COL1A2 and Liver Diseases
Osteoporosis Antibodies	>42 publications with COL1A2 and Osteoporosis
Heart Diseases Antibodies	>39 publications with COL1A2 and Heart Diseases
Liver Cirrhosis Antibodies	>36 publications with COL1A2 and Liver Cirrhosis
Necrosis Antibodies	>33 publications with COL1A2 and Necrosis
Kidney Diseases Antibodies	>27 publications with COL1A2 and Kidney Diseases

Organs/Tissues associated with anti-COL1A2 antibody

Organ/Tissue Name	Pubmed Publications
Bone Antibodies	>326 publications with COL1A2 and Bone
Connective Tissue Antibodies	>217 publications with COL1A2 and Connective Tissue
Skin Antibodies	>214 publications with COL1A2 and Skin
Muscle Antibodies	>97 publications with COL1A2 and Muscle
Blood Antibodies	>88 publications with COL1A2 and Blood
Liver Antibodies	>80 publications with COL1A2 and Liver
Vascular Antibodies	>59 publications with COL1A2 and Vascular
Embryonic Tissue Antibodies	>53 publications with COL1A2 and Embryonic Tissue
Lung Antibodies	>49 publications with COL1A2 and Lung
Kidney Antibodies	>48 publications with COL1A2 and Kidney